刚刚在港交所上市的长风药业（02652.HK）今日盘中大跌5.45%，引发市场关注。这一跌幅与其昨日上市首日161.02%的涨幅形成鲜明对比。
长风药业于10月8日在港交所主板挂牌上市，首日收盘价为38.50港元，较14.75港元的发行价大涨161.02%。公司此次全球发售4119.8万股H股，募集资金净额约为5.25亿港元。作为一家专注于呼吸系统吸入制剂研发的企业，长风药业的产品线覆盖哮喘、慢性阻塞性肺病及过敏性鼻炎等高需求领域。
分析人士指出，今日的大幅下跌很可能是由于投资者在昨日强劲涨幅后选择获利了结。此外，市场可能正在重新评估公司的估值，从IPO的初始兴奋中冷静下来。尽管如此，长风药业作为呼吸系统药物研发领域的重要参与者，其长期发展前景仍值得关注。投资者应密切关注公司未来的研发进展和市场表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.